Ian F. Tannock

机构：University of Toronto, Princess Margaret Cancer Centre · ORCID：0000-0002-2636-7041

发表论文 609 篇 · 总被引 63637 次 · h-index 112

代表论文

• The Lancet Commission on prostate cancer: planning for the surge in cases (2024 · The Lancet · 被引 726)
• Common Sense Oncology: outcomes that matter (2023 · The Lancet Oncology · 被引 108)
• Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs (2023 · Journal of Clinical Oncology · 被引 69)
• Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials (2025 · The Lancet Oncology · 被引 47)
• The tyranny of non-inferiority trials (2024 · The Lancet Oncology · 被引 26)
• Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer (2023 · The Lancet Oncology · 被引 25)